Skip to content
HowShorted

INOVIO PHARMACEUTICALS, INC. short interest in 2022

In 2022, INOVIO PHARMACEUTICALS, INC.'s disclosed short interest ran from 21.26% of shares outstanding on 14 Jan 2022 to 17.94% on 30 Dec 2022, a change of -3.32 percentage points. The year's high was 22.88% on 28 Feb 2022 and its low 15.83% on 31 May 2022, averaging 19.31% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.96 days on 28 Feb 2022. Full history: INOVIO PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for INOVIO PHARMACEUTICALS, INC. in 2022

2022 in figures

Start of year
21.26% (14 Jan 2022)
End of year
17.94% (30 Dec 2022)
Change
-3.32 pp
High
22.88% (28 Feb 2022)
Low
15.83% (31 May 2022)
Average
19.31%
Highest days to cover
13.96 (28 Feb 2022)
SEC filings marked
7

Every report in 2022

INOVIO PHARMACEUTICALS, INC. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202221.26%10.84
31 Jan 202222.35%9.62
15 Feb 202222.34%10.02
28 Feb 202222.88%13.96
15 Mar 202221.27%10.2310-K filed
31 Mar 202220.52%6.86
14 Apr 202220.87%11.39
29 Apr 202220.77%12.43
13 May 202219.92%6.3610-Q filed, results (8-K)
31 May 202215.83%3.67
15 Jun 202216.52%6.43
30 Jun 202218.57%4.94
15 Jul 202220.00%8.11
29 Jul 202220.10%7.17
15 Aug 202218.07%6.6610-Q filed, results (8-K)
31 Aug 202218.28%8.63
15 Sep 202218.34%8.55
30 Sep 202218.01%7.73
14 Oct 202218.27%10.23
31 Oct 202217.51%7.18
15 Nov 202218.50%6.1410-Q filed, results (8-K)
30 Nov 202217.34%7.85
15 Dec 202218.03%8.67
30 Dec 202217.94%7.98

See also: INOVIO PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.